The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Does Methotrexate Increase Skin Cancer Risk?

Does Methotrexate Increase Skin Cancer Risk?

November 16, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270Results from a new study reinforce a longstanding concern that the immunosuppressant and biologic agents commonly used to treat patients with autoimmune disease may increase the risk of nonmelanoma skin cancer (NMSC).

You Might Also Like
  • Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer
  • IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
  • Reassuring Data on Cancer Risk with Contemporary RA Drugs
Also By This Author
  • Insight into Achieving & Maintaining Target Serum Urate Levels in Gout Patients

NMSC, also known as squamous cell carcinoma, is the most frequently diagnosed malignant neoplasm in the U.S. Unfortunately, immunosuppressive therapy is a known risk factor for NMSC. In particular, methotrexate is associated with an increased risk of NMSC in patients with a history of NMSC. Patients with rheumatoid arthritis (RA) and NMSC also have an increased risk for NMSC recurrence when treated with anti-tumor necrosis factor (anti-TNF) and methotrexate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Frank I. Scott, MD, MSCE, assistant professor of medicine at the University of Pennsylvania in Philadelphia, and colleagues questioned whether immunosuppressive treatment regimens were associated with an increased risk for NMSC. The results of their retrospective cohort study were published online on Oct. 28 in JAMA Dermatology.1 The team studied claim-based data from patients with RA and inflammatory bowel disease (IBD) who experienced NMSC, as identified by a combination of diagnostic and procedural codes. They then evaluated the effect of immunosuppressive therapies on the risk of NMSC recurrence.

Methotrexate Increases Risk for NMSC
The investigators identified 6,841 patients with RA, 2,788 patients with IBD and 169 patients with both RA and IBD. A total of 1,291 individuals had NMSC recurrence, yielding an incidence rate of NMSC recurrence of 58.2 per 1,000 person-years in patients with RA and 58.9 per 1,000 person-years in patients with IBD. They calculated that one year or more of methotrexate use (once adjusted for other medications) was associated with an increased risk of NMSC (hazard ratio: 1.24; 95% confidence interval, 1.04–1.48). The median time of methotrexate exposure between the first NMSC and recurrence was 1.64 years. The researchers also observed an increased risk of NMSC with increased duration of methotrexate exposure. The increase was even greater (34 per 1,000 person-years) when methotrexate was used with non-immunosuppressive therapies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In contrast, patients who were treated with methotrexate for RA did not experience a further increase in risk for NMSC recurrence when treated with abatacept or rituximab. However, in the case of patients with RA who were treated with methotrexate and anti-TNFs, the incidence of NMSC recurrence increased significantly, by 19 per 1,000 person-years. Anti-TNF therapy alone was also significantly associated with increased risk for NMSC recurrence in patients with RA. Unfortunately, although the investigators were interested in exploring the effects of such drugs as leflunomide, which were prescribed to these patient populations, the sample size was too small to perform an analysis.

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: Cancer, inflammatory bowel disease, Methotrexate, nonmelanoma skin cancer (NMSC), Rheumatoid Arthritis (RA), rituximab

You Might Also Like:
  • Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer
  • IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
  • Reassuring Data on Cancer Risk with Contemporary RA Drugs
  • TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.